Article Versions Notes

Marković S, Kralj Đ, Svorcan P, Knežević Ivanovski T, Odanović O, Obradović S, Homšek A, Jovanović M, Savić R, Vučićević KM. Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics. Pharmaceutics. 2024; 16(12):1629. https://doi.org/10.3390/pharmaceutics16121629

Marković, Srđan, Đorđe Kralj, Petar Svorcan, Tamara Knežević Ivanovski, Olga Odanović, Sanja Obradović, Ana Homšek, Marija Jovanović, Rada Savić, and Katarina M. Vučićević. 2024. "Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics" Pharmaceutics 16, no. 12: 1629. https://doi.org/10.3390/pharmaceutics16121629

Marković, S., Kralj, Đ., Svorcan, P., Knežević Ivanovski, T., Odanović, O., Obradović, S., Homšek, A., Jovanović, M., Savić, R., & Vučićević, K. M. (2024). Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics. Pharmaceutics, 16(12), 1629. https://doi.org/10.3390/pharmaceutics16121629